These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 508779)

  • 21. Infantile Gaucher's disease: a case with neuronal storage.
    Grafe M; Thomas C; Schneider J; Katz B; Wiley C
    Ann Neurol; 1988 Mar; 23(3):300-3. PubMed ID: 2837134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Gaucher's disease - an overview about a sphingolipidosis].
    Tamò R; Hochuli M; Beuschlein F; Nowak A
    Ther Umsch; 2018 Nov; 75(4):209-214. PubMed ID: 30468119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucosylceramide and glucosylsphingosine metabolism in cultured fibroblasts deficient in acid beta-glucosidase activity.
    Sasagasako N; Kobayashi T; Yamaguchi Y; Shinnoh N; Goto I
    J Biochem; 1994 Jan; 115(1):113-9. PubMed ID: 8188616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sphingomyelin and glucocerebroside of spleen in cases of Gaucher's and Niemann-Pick's diseases.
    Taketomi T; Yamakawa T
    Jpn J Exp Med; 1967 Oct; 37(5):505-9. PubMed ID: 5303496
    [No Abstract]   [Full Text] [Related]  

  • 25. Studies of the pathogenesis of Gaucher's disease: tissue distribution and biliary excretion of [14C]L-glucosylceramide in rats.
    Tokoro T; Gal AE; Gallo LL; Brady RO
    J Lipid Res; 1987 Aug; 28(8):968-72. PubMed ID: 3668390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The distribution of glucocerebroside in the liver of patients with Gaucher's disease.
    Gal AE; Pentchev PG; Barranger JA; Dambrosia JM; Brady RO
    Anal Biochem; 1979 May; 95(1):127-32. PubMed ID: 495946
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of N-acyl phosphatidylethanolamines with different N-acyl groups as activators of glucocerebrosidase in various forms of Gaucher's disease.
    Basu A; Prence E; Garrett K; Glew RH; Ellingson JS
    Arch Biochem Biophys; 1985 Nov; 243(1):28-34. PubMed ID: 3933429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sucrose gradient analysis of phospholipid-activated beta-glucosidase in type 1 and type 2 Gaucher's disease.
    Garrett KO; Prence EM; Glew RH
    Arch Biochem Biophys; 1985 Apr; 238(1):344-52. PubMed ID: 3920967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lysosome-targeted octadecyl-rhodamine B-liposomes enhance lysosomal accumulation of glucocerebrosidase in Gaucher's cells in vitro.
    Thekkedath R; Koshkaryev A; Torchilin VP
    Nanomedicine (Lond); 2013 Jul; 8(7):1055-65. PubMed ID: 23199221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activators of spleen glucocerebrosidase from controls and patients with various forms of Gaucher's disease.
    Basu A; Glew RH; Daniels LB; Clark LS
    J Biol Chem; 1984 Feb; 259(3):1714-9. PubMed ID: 6693432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The assay of glucocerebrosidase activity using the natural substrata.
    Strasberg PM; Lowden JA
    Clin Chim Acta; 1982 Jan; 118(1):9-20. PubMed ID: 7053909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitors and stimulators of glucocerebroside metabolism.
    Radin NS
    Prog Clin Biol Res; 1982; 95():357-83. PubMed ID: 6214799
    [No Abstract]   [Full Text] [Related]  

  • 33. Gaucher's disease and glioblastoma multiforme in two siblings: a clinicopathologic study.
    Lyons JC; Scheithauer BW; Ginsburg WW
    J Neuropathol Exp Neurol; 1982 Jan; 41(1):45-53. PubMed ID: 6275038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Splenic lipids in Gaucher's disease.
    Kennaway NG; Woolf LI
    J Lipid Res; 1968 Nov; 9(6):755-65. PubMed ID: 5685267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acid phosphatase isoenzymes in Gaucher's disease.
    Mercer DW; Peters SP; Glew RH; Lee RE; Wenger DM
    Clin Chem; 1977; 23(4):631-5. PubMed ID: 844157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pathogenic mechanism and therapies for Gaucher's disease].
    Liu LY; Du SC; Zhang J; Ma D
    Yi Chuan; 2015 Jun; 37(6):510-6. PubMed ID: 26351046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Purification and characterization of a cytosolic broad specificity beta-glucosidase from human liver.
    Daniels LB; Coyle PJ; Chiao YB; Glew RH; Labow RS
    J Biol Chem; 1981 Dec; 256(24):13004-13. PubMed ID: 6796580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Taliglucerase alfa for the treatment of Gaucher's disease.
    Haddley K
    Drugs Today (Barc); 2012 Aug; 48(8):525-32. PubMed ID: 22916340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Neurological manifestations of type 1 Gaucher's disease: Is a revision of disease classification needed?].
    Chérin P; Sedel F; Mignot C; Schupbach M; Gourfinkel-An I; Verny M; Baumann N
    Rev Neurol (Paris); 2006 Nov; 162(11):1076-83. PubMed ID: 17086144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gaucher's disease in the presence of normal glucocerebrosidase activity.
    Schofield DE; Scott CR; Lage JM; Farrell DF
    Hum Pathol; 1992 May; 23(5):588-92. PubMed ID: 1568755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.